Barclays PLC Spring Works Therapeutics, Inc. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 156,123 shares of SWTX stock, worth $7.41 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
156,123
Previous 155,676
0.29%
Holding current value
$7.41 Million
Previous $4.99 Million
13.11%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding SWTX
# of Institutions
235Shares Held
67.2MCall Options Held
260KPut Options Held
316K-
Vanguard Group Inc Valley Forge, PA7.16MShares$340 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$267 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.46MShares$164 Million5.51% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.27MShares$156 Million0.01% of portfolio
-
State Street Corp Boston, MA3MShares$143 Million0.0% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.96B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...